Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMKSU35)

Drug Name
PU-AD Drug Info
Indication
Disease Entry ICD 11 Status REF
Encephalopathy 8E47 Phase 1 [1]
Alzheimer disease 8A20 Phase 0 [1]
Cross-matching ID
TTD Drug ID
DMKSU35

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Heat shock protein 90 alpha (HSP90A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cromoglicate DM74LZK Asthma CA23 Approved [2]
Amlexanox DM0DQM5 Respiratory tract inflammation CA07 Approved [2]
NVP-AUY922 DMTYXQF Multiple myeloma 2A83 Phase 2 [3]
BIIB-021 DMPAJ41 Breast cancer 2C60-2C65 Phase 2 [4]
KW-2478 DMJGL72 Solid tumour/cancer 2A00-2F9Z Phase 2 [5]
VER 50589 DMFLZPC Breast cancer 2C60-2C65 Phase 2 [3]
Tanespimycin DMNLQHK Breast cancer 2C60-2C65 Phase 2 [6]
Efungumab DMBHP56 Breast cancer 2C60-2C65 Phase 2 [7]
SNX-5422 DMIU0VP Haematological malignancy 2B33.Y Phase 1/2 [8]
PU3 DMJO0BP Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Heat shock protein 90 alpha (HSP90A) TT78R5H HS90A_HUMAN Inhibitor [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Hsp90 is a direct target of the anti-allergic drugs disodium cromoglycate and amlexanox. Biochem J. 2003 Sep 1;374(Pt 2):433-41.
3 Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82.
4 BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther. 2009 Apr;8(4):921-9.
5 Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib. Blood Cancer J. 2012 Apr;2(4):e68.
6 Tanespimycin: the opportunities and challenges of targeting heat shock protein 90. Expert Opin Investig Drugs. 2009 Jun;18(6):861-8.
7 Efungumab: a novel agent in the treatment of invasive candidiasis. Ann Pharmacother. 2009 Nov;43(11):1818-23.
8 SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hema... Blood. 2009 Jan 22;113(4):846-55.